Alligator Bioscience Q2 2023: Positive Second Interim Readout - Redeye

Redeye is convinced by the second interim readout of mitazalimab in which the objective response rate was 44% based on 57 patients. Alligator is now intensifying business development activities to find a partner for mitazalimab before Q2 2024. Cost have increased, however, and the cash position is somewhat weak despite the recent rights issue. We have updated our Base and Bear Case taking this into consideration.

Länk till analysen i sin helhet: https://www.redeye.se/research/921475/alligator-bioscience-q2-2023-positive-second-interim-readout?utm_source=finwire&utm_medium=RSS